Trump links pharma reshoring and chip fab to $265 billion Arizona deal

In the same speech, Trump shifted focus to the pharmaceutical sector, noting that major U.S. drug makers such as Eli Lilly, Merck and Pfizer are moving production back from Ireland, China and the United Kingdom. He claimed the "most‑favoured‑nation" pricing policy has already cut drug prices by 50‑80 percent, though he offered no statistics. The president tied these reshoring moves to the $265 billion TSMC investment, suggesting a broader wave of American manufacturing revival across high‑tech and health industries.